Vasopressin Use in Septic Shock From Türkiye
Key facts
- Who runs it
- Karadeniz Technical University
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 146 people enrolled
- Started
- 1 Jan 2024
- Ended
- 15 Jan 2025
- Type of study
- Observational, 2 groups
- Record updated
- 1 May 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Adult patients (≥18 years old) admitted to the intensive care unit (ICU)
- Diagnosed with septic shock according to Sepsis-3 criteria
- Treated with norepinephrine as the initial vasopressor
- Received norepinephrine alone or norepinephrine with adjunctive vasopressin
- Admitted between January 1 and December 15, 2024
Who cannot take part
- Patients who received epinephrine or dopamine prior to or along with vasopressin
- Patients younger than 18 years
- Patients with incomplete clinical or hemodynamic data
- Readmitted ICU patients during the same hospitalization
- Patients with do-not-resuscitate (DNR) orders at ICU admission
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this observational study is to examine the early hemodynamic effects and clinical outcomes of vasopressin use in patients with septic shock. The study aims to compare adult ICU patients who received norepinephrine alone versus those who received vasopressin in addition to norepinephrine.
Read full original descriptionShow less
The main question it aims to answer is:
Does adding vasopressin to norepinephrine improve blood pressure, lactate levels, and survival in patients with septic shock?
Researchers used retrospective medical records of patients treated between January and December 2024. Data such as blood pressure, heart rate, lactate levels, and mortality were collected and analyzed to assess treatment response and outcomes.
The 2 groups in the trial
- Norepinephrine Only
Participants with septic shock who received norepinephrine as the sole vasopressor agent during their ICU stay. No adjunctive vasopressin or other vasopressors were administered. This group served as the reference for comparison of hemodynamic and clinical outcomes.
- Norepinephrine Plus Vasopressin
Participants with septic shock who received adjunctive vasopressin in addition to norepinephrine. Vasopressin was initiated during the course of vasodilatory shock based on clinical judgment. The study evaluated hemodynamic response and mortality in this group compared to norepinephrine monotherapy.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Exploring Vasopressin Use in Septic Shock: A Retrospective Cohort Study From Türkiye
- Publications
- Record updated
- 1 May 2025